A Phase 1 interventional study of DWP212525 XXmg and DWP212525 placebo in Autoimmune Diseases, sponsored by Daewoong Pharmaceutical Co. LTD.. Recruiting at 1 site in South Korea. Open to participants aged 19 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-08.
Sponsored by Daewoong Pharmaceutical Co. LTD. · Phase 1, Interventional, and Treatment
The safety and tolerability of single and multiple administration of DWP212525
The safety and tolerability of single and multiple administration of DWP212525 will be evaluated in healthy adult volunteers.
802 studies on the registry are indexed under Autoimmune Diseases; 271 are open to participants now.
This study's planned enrollment of 84 is above the median of 40 across 541 interventional studies indexed under Autoimmune Diseases.
Browse Autoimmune Diseases studies →Daewoong Pharmaceutical Co. LTD. is the lead sponsor of 200 studies on the registry; 33 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: DWP212525 XXmg · Drug: DWP212525 placebo
Drug: DWP212525 XXmg · Drug: DWP212525 placebo
Drug: DWP212525 XXmg · Drug: DWP212525 placebo
Drug: DWP212525 XXmg · Drug: DWP212525 placebo
Drug: DWP212525 XXmg · Drug: DWP212525 placebo
Drug: DWP212525 XXmg · Drug: DWP212525 placebo
Drug: DWP212525 XXmg · Drug: DWP212525 placebo
Drug: DWP212525 XXmg · Drug: DWP212525 placebo
Drug: DWP212525 XXmg · Drug: DWP212525 placebo
Drug: DWP212525 XXmg · Drug: DWP212525 placebo
Drug: DWP212525 XXmg · Drug: DWP212525 placebo
DWP212525 XXmg
DWP212525 placebo
PK profiles of DWP212525
Area under the plasma drug concentration-time curve from 0 to last
Time frame: Day 1
PK profiles of DWP212525
The maximum or peak concentration between zero and dosing interval
Time frame: Day 1
PK profiles of DWP212525
Time of maximum concentration
Time frame: Day 1
Safety profiles
AE, SAE, etc.
Time frame: Day 1
Plan to share: No
No publications or documents are linked to this record.
Started Dec 2024 (actual). Primary completion is estimated for Dec 2026, 24 months after the start.
Of 68 industry-sponsored phase 1 interventional studies under Autoimmune Diseases, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 32. This study's planned 24 months is above that.
Counting every sponsor, half of 94 studies reached it within 23 months; a quarter within 9 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Daewoong Pharmaceutical Co. LTD. →